New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
09:19 EDTSHPG, AZN, SNN, WAGShire, AstraZeneca, Smith & Nephew slump amid inversion fears, FT says
Shares of several companies that may be impacted by increased scrutiny of "tax inversion" deals by U.S. lawmakers fell in U.K. trading, including Shire (SHPG), AstraZeneca (AZN), and Smith & Nephew (SNN), reported Financial Times. The slumps come after the U.S. Treasury said it was “reviewing a broad range of authorities for possible administrative action” to limit inversions and after Walgreen (WAG) decided it would not pursue an inversion as part of its deal to acquire the remaining stake in Alliance Boots that it does not already own. Reference Link
News For SHPG;AZN;SNN;WAG From The Last 14 Days
Check below for free stories on SHPG;AZN;SNN;WAG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 16, 2014
10:19 EDTAZNFDA approves Movantik with requirement for cardiovascular risk study
Subscribe for More Information
08:12 EDTWAGWalgreen files S-4, prospectus for strategic transaction with Alliance Boots
Subscribe for More Information
08:00 EDTAZNFDA PDUFA Date for Nektar and AstraZeneca''s Movantik is September 16, 2014
07:31 EDTAZNEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:02 EDTAZNEli Lilly and AstraZeneca to co-develop and commercialize AZD3293
Subscribe for More Information
06:27 EDTAZNAstraZeneca, Eli Lilly to jointly develop, commercialize AZD3293
AstraZeneca (AZN) and Eli Lilly (LLY) announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in development as a potential treatment for Alzheimer's disease. AZD3293 has been shown in Phase I studies to significantly and dose-dependently reduce levels of amyloid beta in the cerebro-spinal fluid of Alzheimer's patients and healthy volunteers. AstraZeneca announced earlier in 2014 its plan to move AZD3293 into registration trials. Under the terms of the agreement, Lilly will pay AstraZeneca up to $500M in development and regulatory milestone payments. AstraZeneca expects to receive the first milestone payment of $50M in the 1H15. The companies will share all future costs equally for the development and commercialization of AZD3293, as well as net global revenues post-launch. AstraZeneca and Lilly aim to progress AZD3293 rapidly into a Phase II/III clinical trial in patients with early Alzheimer's disease. Lilly will lead clinical development, working with researchers from AstraZeneca's Innovative Medicines Unit for neuroscience, while AstraZeneca will be responsible for manufacturing. The companies will take joint responsibility for commercialization of AZD3293. The agreement is subject to customary terms and conditions. It will have no impact on AstraZeneca's 2014 Core Earnings per Share.
September 15, 2014
10:55 EDTSHPGRegulators to determine AbbVie, Shire deal by next month, Reuters says
Subscribe for More Information
08:01 EDTSHPGShire announces FDA acceptance for filing of sNDA for Vyvanse
Subscribe for More Information
07:27 EDTAZNPfizer acquisition could drive shares higher, says JPMorgan
Subscribe for More Information
September 12, 2014
18:43 EDTWAGCtW Investment calls on Walgreen to provide details on earnings, Reuters says
Subscribe for More Information
10:32 EDTAZNPfizer CEO says company still open to inversion deal, FT says
Pfizer (PFE) CEO Ian Read said U.S. rhetoric against tax inversions has been "political theater" ahead of midterm elections and made clear that his company is still open to a potential tax-saving acquisition, according to Financial Times, which added Read's comment about not being “held hostage” over price would likely be read as a signal the company might look elsewhere after being rebuffed by AstraZeneca (AZN). The Fly notes that Bloomberg previously reported, citing people familiar with the matter, that Pfizer is looking at targets other than AstraZeneca, including Actavis (ACT). Shares of Actavis trading in New York are up 2% this morning. Reference Link
September 10, 2014
15:21 EDTAZNAstraZeneca has a conference call hosted by JPMorgan
Subscribe for More Information
08:37 EDTSHPGMedgenics appoints Scott Applebaum as Chief Legal Officer
Subscribe for More Information
07:06 EDTSHPGSangamo plans to submit IND application for hemophilia B in 2Q15
Sangamo BioSciences (SGMO) plans to submit an Investigational New Drug application for the treatment of hemophilia B in Q2 2015. This program, partnered with Shire (SHPG), is the first therapeutic application of Sangamo's zinc finger nuclease-mediated In Vivo Protein Replacement Platform. Sangamo is developing the IVPRP as a generally applicable strategy to provide a one-time, permanent genetic cure for monogenic diseases that are currently managed by protein replacement therapy, which involves costly repeat infusions over the lifetime of the patient.
September 9, 2014
08:00 EDTWAGWalgreen price target lowered to $75 from $85 at Leerink
Subscribe for More Information
07:38 EDTWAGWalgreen pushed to boost buyback as Jana secures seats, Bloomberg says
Walgreen will most likely be pushed to increase a to $3B share buyback program that let down investors in August after Jana Partners reached an agreement on three board seats at the company, according to Bloomberg, citing a person familiar with the matter. Reference Link
September 8, 2014
14:13 EDTAZNConnecticut AG tells FDA to speed up generic Nexium
A news release from the Connecticut Attorney General George Jepsen, dated September 4, says: In comments to a Citizen Petition filed with the FDA, Attorney General George Jepsen called on the federal agency to expeditiously end several years of delays preventing the sale of a generic form of the drug esomeprazole magnesium , esomeprazole, currently marketed under the brand name Nexium. Nexium is the second highest-selling pharmaceutical drug in the United States, and delays in approving generic versions have cost consumers and government healthcare payers billions of dollars. In his comments, Attorney General Jepsen alleges that an agreement between drug manufacturers Ranbaxy (RBXLY) and AstraZeneca Pharmaceuticals (AZN), Nexium’s brand-name manufacturer, has prevented other drug-makers from launching a generic version of the drug, ultimately harming all consumers by artificially inflating prices. Ranbaxy was first-to-file with the FDA for approval of a generic form of Nexium. AstraZeneca sued Ranbaxy for patent infringement, and the dispute was settled by an agreement that provided financial incentives for Ranbaxy to delay entry of its generic into the consumer market. Reference Link
07:02 EDTAZNAstraZeneca announces availability of Bydureon pen 2mg
Subscribe for More Information
06:54 EDTWAGWalgreen appoints JANA's Barry Rosenstein to board of directors
Subscribe for More Information
05:50 EDTWAGStocks with implied volatility movement; DE WAG
Stocks with implied volatility movement; Deere (DE) 15, Walgreen (WAG) 30 according to iVolatility.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use